PHASEBIO PHARMACEUTICALS INC's ticker is PHAS and the CUSIP is 717224109. A total of 52 filers reported holding PHASEBIO PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.42 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,169,000 | -70.7% | 6,643,702 | 0.0% | 0.06% | -71.7% |
| Q2 2022 | $3,986,000 | -54.5% | 6,643,702 | 0.0% | 0.20% | -19.0% |
| Q1 2022 | $8,770,000 | -49.4% | 6,643,702 | -0.0% | 0.25% | -27.7% |
| Q4 2021 | $17,340,000 | -16.1% | 6,643,704 | 0.0% | 0.35% | +42.9% |
| Q3 2021 | $20,662,000 | -16.4% | 6,643,704 | 0.0% | 0.24% | -23.9% |
| Q2 2021 | $24,715,000 | +7.5% | 6,643,704 | 0.0% | 0.32% | -37.6% |
| Q1 2021 | $22,987,000 | +3.0% | 6,643,704 | 0.0% | 0.52% | -12.4% |
| Q4 2020 | $22,323,000 | -4.3% | 6,643,704 | 0.0% | 0.59% | -40.3% |
| Q3 2020 | $23,319,000 | -23.7% | 6,643,704 | 0.0% | 0.99% | -19.7% |
| Q2 2020 | $30,561,000 | +39.0% | 6,643,704 | 0.0% | 1.23% | +7.0% |
| Q1 2020 | $21,991,000 | -45.8% | 6,643,704 | 0.0% | 1.15% | -40.2% |
| Q4 2019 | $40,593,000 | +46.5% | 6,643,704 | 0.0% | 1.92% | -16.3% |
| Q3 2019 | $27,704,000 | -68.2% | 6,643,704 | 0.0% | 2.29% | -62.4% |
| Q2 2019 | $87,165,000 | – | 6,643,704 | – | 6.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 1,607,044 | $4,194,000 | 0.48% |
| NEA Management Company, LLC | 6,643,704 | $17,340,000 | 0.35% |
| Platform Technology Partners | 251,723 | $657,000 | 0.29% |
| DAFNA Capital Management LLC | 378,611 | $988,000 | 0.25% |
| Avidity Partners Management LP | 4,405,000 | $11,497,000 | 0.24% |
| Endurant Capital Management LP | 360,078 | $940,000 | 0.23% |
| Rock Springs Capital Management LP | 2,581,299 | $6,737,000 | 0.16% |
| RA Capital Management | 2,850,000 | $7,439,000 | 0.13% |
| New Legacy Group, LLC | 240,575 | $628,000 | 0.12% |
| XTX Topco Ltd | 15,574 | $41,000 | 0.02% |